Simultaneous Macroamylasemia and Macrolipasemia in a Patient with Systemic Lupus Erythematosus in Remission

• Published in: Internal Medicine Vol. 39; no. 12; pp. 1115 - 1118
• Main Authors: GOTO, Hiroyuki, WAKUI, Hideki, KOMATSUDA, Atsushi, IMAI, Hirokazu, MIURA, Akira B., FUJITA, Kiyotaka
• Format: Journal Article
• Language: English
• Published: Tokyo The Japanese Society of Internal Medicine 01.12.2000; Japanese Society of Internal Medicine
• Subjects: Adult; Amylases - blood; Antibody Specificity; Antigen-Antibody Complex - blood; Autoantibodies - blood; Autoantibodies - immunology; Autoantigens - blood; Autoantigens - immunology; Autoimmune Diseases - drug therapy; Autoimmune Diseases - enzymology; Autoimmune Diseases - immunology; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; enzyme-linked immunoglobulins; Female; Humans; IgA2; IgAl; Immunoglobulin A - blood; Immunoglobulin A - immunology; Immunoglobulin kappa-Chains - blood; Immunosuppressive Agents - therapeutic use; Lipase - blood; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - enzymology; Lupus Erythematosus, Systemic - immunology; Medical sciences; Molecular Weight; Neurology; Prednisolone - therapeutic use; Protein Binding; Remission Induction; Human; Steroid; Immunopathology; Connective tissue disease; Skin disease; Autoimmune disease; Case study; Macroamylasemia; Systemic disease; Renal failure; Lupus erythematosus; Disseminated; Pancreatic disease
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.39.1115

We report the fourth case of simultaneous macroamylasemia and macrolipasemia. A 39-year-old woman had been treated for systemic lupus erythematosus from 1982 to 1993. She was found to have an unexplained increase in serum amylase and lipase activities since 1996. Immunoprecipitation assay showed that amylase was bound to IgA2-κ and IgA1-κ (IgA2>IgAl), whereas lipase was bound to IgAl-κ. During a follow-up period up to December 1999, the patient did not develop any additional autoimmune or lymphoproliferative disorders. In the situation of atypical clinical features associated with hyperamylasemia and hyperlipasemia, the possibility of macroenzymes should be considered. (Internal Medicine 39:1115-1118, 2000)